Minerva Neurosciences (4MNA) Price & Analysis

0 Followers

4MNA Stock Chart & Stats

€3.83

-€0.18(-4.82%)

At close: Jul 30 4:00 PM EDT

€3.83

-€0.18(-4.82%)

Day’s Range― - ―

52-Week Range€1.94 - €9.85

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€123.54M

Enterprise Value€435.40M

Total Cash (Recent Filing)€75.27M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta1.38

Next Earnings

Nov 11, 2026

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-28.37

Shares Outstanding47,747,560

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)-0.24

Price to Sales (P/S)0.00

P/FCF Ratio>-0.01

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€7.61

Price Target Upside98.70% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-3.09

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

CNS Pipeline FocusA focused CNS strategy targets serious psychiatric and neurological conditions where unmet medical needs can support continued development activity. If candidates advance successfully, this specialization gives Minerva a clear therapeutic mission and a potential route to meaningful commercialization.

Accounting LeadershipFormalizing accounting leadership and separating accounting responsibility from the CFO role may strengthen reporting oversight and internal-control discipline. The change is relevant beyond a single reporting period because clearer accountability can support governance quality as the company advances its capital-intensive pipeline.

Expanded Asset BaseSubstantially higher total assets provide a larger reported resource base than in prior periods and may support ongoing research and development activity. However, the benefit is tempered by the company’s strained capital structure, so asset growth does not eliminate its broader financing constraints.

Bears Say

No Recurring RevenueThe absence of recurring revenue means Minerva has not yet demonstrated a commercial income engine to fund operations or validate sustainable demand. Persistent operating losses across the reported periods leave future progress dependent on successful development, approval, and eventual commercialization.

Persistent Cash BurnOngoing negative operating and free cash flow indicates that the business consumes cash rather than financing itself internally. Accelerating burn increases the amount of capital required to sustain clinical development and raises the risk that future financing could constrain strategic flexibility.

Negative EquityDeepening negative equity signals a weak capital position and limits financial resilience during continued clinical investment. Although total debt is mostly low or zero except in 2025, the balance-sheet deficit can increase dependence on external funding and restrict future capital-allocation choices.

Minerva Neurosciences News

Minerva upgraded to Buy from Hold at Jefferies

Jefferies upgraded Minerva (NERV) to Buy from Hold with a price target of $10, up from $7.50. The...

2M ago

NERV

Minerva Neurosciences Elevates Aliquo to Accounting Leadership

Minerva Neurosciences ( ($NERV) ) just unveiled an announcement. On August 10, 2026, Minerva Neurosciences’ board appointed Vice...

2M ago

NERV

NERV Earnings this Week: How Will it Perform?

Minerva Neurosciences (NERV) is scheduled to report 2nd quarter earnings on 08/04/2026. Regarding Q2 estimates, Wall Street analysts...

2M ago

NERV

Fourteen new option listings and one option delisting on July 22nd

New option listings for July 22nd include Tradr 2X Short AAOI Daily ETF (AAOZ), Alpha Cognition Inc (ACOG),...

3M ago

ACOG

ARTV

Minerva management to meet with Citizens

Meeting to be held in Boston on July 16 hosted by Citizens. Published first on TheFly – the...

3M ago

NERV

Minerva Neurosciences Updates Governance Following 2026 Shareholder Meeting

Minerva Neurosciences ( ($NERV) ) has provided an announcement. On June 3, 2026, Minerva Neurosciences held its 2026...

4M ago

NERV

Minerva Neurosciences Launches ATM Offering to Fund Trial

Minerva Neurosciences ( ($NERV) ) has shared an announcement. On May 27, 2026, Minerva Neurosciences, Inc. entered into...

5M ago

NERV

Minerva Neurosciences Launches Key Phase 3 Test for Roluperidone in Schizophrenia

Minerva Neurosciences ($NERV) announced an update on their ongoing clinical study. Minerva Neurosciences is running a Phase 3...

5M ago

NERV

Tsao Maintains Hold on Minerva as Roluperidone Phase 3 Progress Balances Rising Losses; $7 Price Target Reaffirmed

H.C. Wainwright analyst Douglas Tsao reiterated a Hold rating on Minerva Neurosciences today and set a price target...

5M ago

NERV

NERV Earnings this Week: How Will it Perform?

Minerva Neurosciences (NERV) is scheduled to report 1st quarter earnings on 05/06/2026. Regarding Q1 estimates, Wall Street analysts...

5M ago

NERV

Minerva initiated with an Outperform at Citizens

Citizens initiated coverage of Minerva (NERV) with an Outperform rating and $14 price target Minerva is developing roluperidone...

6M ago

NERV

Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline

Minerva Neurosciences ( ($NERV) ) just unveiled an update. Minerva Neurosciences, Inc. announced that its 2026 annual meeting...

6M ago

NERV

Minerva Neurosciences Appoints New Chief Business Officer, Counsel

Minerva Neurosciences ( ($NERV) ) has shared an update. On March 30, 2026, Minerva Neurosciences reached a settlement...

6M ago

NERV

Minerva appoints Jim O’Connor as chief business officer

Minerva (NERV) announced a leadership transition with the appointment of Jim O’Connor as chief business officer, effective April...

6M ago

NERV

4MNA FAQ

What was Minerva Neurosciences’s price range in the past 12 months?

Minerva Neurosciences lowest stock price was €1.94 and its highest was €9.85 in the past 12 months.

What is Minerva Neurosciences’s market cap?

Minerva Neurosciences’s market cap is €123.54M.

When is Minerva Neurosciences’s upcoming earnings report date?

Minerva Neurosciences’s upcoming earnings report date is Nov 11, 2026 which is in 28 days.

How were Minerva Neurosciences’s earnings last quarter?

Minerva Neurosciences released its earnings results on Aug 07, 2026. The company reported -€0.125 earnings per share for the quarter, beating the consensus estimate of -€0.173 by €0.047.

Is Minerva Neurosciences overvalued?

According to Wall Street analysts Minerva Neurosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Minerva Neurosciences pay dividends?

Minerva Neurosciences does not currently pay dividends.

What is Minerva Neurosciences’s EPS estimate?

Minerva Neurosciences’s EPS estimate is -0.15.

How many shares outstanding does Minerva Neurosciences have?

Minerva Neurosciences has 47,747,560 shares outstanding.

What happened to Minerva Neurosciences’s price movement after its last earnings report?

Minerva Neurosciences reported an EPS of -€0.125 in its last earnings report, beating expectations of -€0.173. Following the earnings report the stock price went up 1.904%.

Which hedge fund is a major shareholder of Minerva Neurosciences?

Currently, no hedge funds are holding shares in DE:4MNA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Minerva Neurosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

250.02%

Trailing 12-Months

Asset Growth

212.59%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Minerva Neurosciences

Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.

Minerva Neurosciences (4MNA) Earnings & Revenues

Historic Earnings Reports

4MNA Stock 12 Month Forecast

Average Price Target

€7.61

▲(98.70% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","9":"€9","2.25":"€2.25","4.5":"€4.5","6.75":"€6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.9530164,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€8.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.61006394,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€7.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.26711148,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€6.27</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.818,3.2899243384615384,3.761848676923077,4.233773015384616,4.705697353846154,5.177621692307692,5.649546030769231,6.121470369230769,6.593394707692307,7.065319046153846,7.537243384615385,8.009167723076922,8.481092061538462,{"y":8.9530164,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.818,3.186620303076923,3.555240606153846,3.9238609092307692,4.292481212307693,4.661101515384615,5.029721818461539,5.398342121538462,5.766962424615385,6.135582727692308,6.504203030769231,6.872823333846155,7.241443636923078,{"y":7.61006394,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.818,3.083316267692308,3.348632535384615,3.613948803076923,3.8792650707692307,4.144581338461538,4.409897606153846,4.675213873846154,4.940530141538462,5.2058464092307695,5.471162676923077,5.736478944615384,6.001795212307692,{"y":6.26711148,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.68,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.46,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.38,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.34,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.118,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.75,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.408,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.834,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.818,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >